The 2026 Canadian Nephrology Trials Network Research Symposium at the Canadian Society of Nephrology AGM pre-course on Wednesday, May 6, is open for registration.
This hybrid event is your opportunity to:
-
Hear updates from ongoing and upcoming clinical trials in Canada
-
Learn what’s ahead for CNTN, and find out how you can get involved
-
Foster collaboration among researchers, trainees, and patient partners
There will be presentations from:
- Kevin Yau – GUARD-1: This study tests semaglutide in people on dialysis to see how safe and easy it is to use. Researchers will also look at Ontario health data to check for possible side effects of semaglutide and finerenone, such as low blood sugar, gallbladder issues, vision changes, or high potassium.
- Cal Robinson – KIDBP Committee and upcoming trials : The KIDBP-Trials Committee within CNTN is being developed to guide clinical trials on childhood kidney disease and high blood pressure. It will focus on practical studies that answer real-world questions for children, families, clinicians, and health systems.
- Drs. Christine A. White/ Rachel Holden – DLITE: Multicenter RCT to determine whether twice-weekly HD compared to thrice-weekly HD, maintains Days Alive and Out of the Hospital (DAOH), which is an important patient-centered goal and outcome that approximates time spent at home.
Please note the CNTN Research Symposium is open to all, with limited in-person capacity. Register early. Virtual attendance is available.
Questions? Contact CNTN Research Coordinator Omo Enilama at omo.enilama@phc.ca.